Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to Ensure Market Access to Predictive Biomarker Test for New Immuno-Oncology (IO) Therapy for Advanced Bladder Cancer
15 mai 2017 07h00 HE | Cancer Genetics, Inc.
RUTHERFORD, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in precision diagnostics for oncology, announced today that it has partnered...
Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. Announces 15% Revenue Increase in First Quarter of 2017 over 2016 on Strong Organic Growth While Continuing on Path to Profitability
11 mai 2017 18h23 HE | Cancer Genetics, Inc.
Revenue increased to $7.0 million in Q1 2017, up 15% compared to Q1 2016 on strong organic growthTest volumes increased 19% year-over-year to 12,310Gross profit margin was 40%, up from 32% for Q1...
Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. Changes The Paradigm For Lung Cancer Monitoring – Launches Clinically Actionable, Multi-Gene, Liquid Biopsy Test For Lung Cancer Patients, Liquid::Lung-cfDNA™
08 mai 2017 07h32 HE | Cancer Genetics, Inc.
CGI has launched the multi-gene, next-generation sequencing (NGS) panel with CLIA validation, and will perform the test for both clinical care and for trials being performed by biotech and...
Cancer Genetics, Inc. Logo
Cancer Genetics to Hold First Quarter 2017 Earnings Call on Friday, May 12th
05 mai 2017 08h48 HE | Cancer Genetics, Inc.
RUTHERFORD, N.J., May 05, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today...
Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. to Present at The Pioneers 2017 Conference Presented by Joseph Gunnar & Co., LLC
25 avr. 2017 07h00 HE | Cancer Genetics, Inc.
RUTHERFORD, N.J., April 25, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through molecular markers and...
Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. Launches a Unique, Industry-Leading Panel That Provides Comprehensive & Precise Information for Immuno-Oncology Therapy Assessment & Patient Monitoring
24 avr. 2017 07h19 HE | Cancer Genetics, Inc.
Complete::IOTM provides immune endpoint and immune monitoring of patients allowing informed therapeutic decisions and assessment of potential toxicities of IO therapies in blood cancers and solid...
Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. is Selected by eFFECTOR Therapeutics to Provide Biomarker Discovery and Development Services for Novel Oncology Drugs
10 avr. 2017 07h00 HE | Cancer Genetics, Inc.
RUTHERFORD, N.J. and SAN DIEGO, April 10, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) (“CGI” or “The Company”), a leader in enabling precision medicine for oncology through...
Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. and Mendel.ai Announce Strategic Partnership Enabling Artificial Intelligence in Precision Medicine to Drive Personalized Treatment and Accelerate Clinical Trial Matching for Cancer Care
03 avr. 2017 07h00 HE | Cancer Genetics, Inc.
Powerful New Capability Leverages Artificial Intelligence & Big Data Analytics to Accelerate and Democratize Access to Clinical Trials for CancerCGI and Mendel.ai will be Among the First in...
Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. to Present at The MicroCap Conference on April 4th at 08:00 AM in New York City
28 mars 2017 16h10 HE | Cancer Genetics, Inc.
RUTHERFORD, N.J., March 28, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced...
Cancer Genetics, Inc. Logo
Cancer Genetics, Inc. Announces Record Revenue for Fourth Quarter and Full-Year 2016 and Provides 2017 Business Update
23 mars 2017 07h30 HE | Cancer Genetics, Inc.
Full-year 2016 revenues up 50% year-over-year to $27 million from $18 millionFourth quarter revenues up 32% year-over-year on strong organic growth to $7.2 millionFourth quarter gross profit margins...